BE644455A - - Google Patents
Info
- Publication number
- BE644455A BE644455A BE644455A BE644455A BE644455A BE 644455 A BE644455 A BE 644455A BE 644455 A BE644455 A BE 644455A BE 644455 A BE644455 A BE 644455A BE 644455 A BE644455 A BE 644455A
- Authority
- BE
- Belgium
- Prior art keywords
- emi
- culture
- coli
- lyophilization
- pathogenic
- Prior art date
Links
- 241000588724 Escherichia coli Species 0.000 claims description 8
- 230000001717 pathogenic effect Effects 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 4
- 210000000936 intestine Anatomy 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 235000021317 phosphate Nutrition 0.000 claims description 2
- 238000009630 liquid culture Methods 0.000 claims 2
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000012928 buffer substance Substances 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- -1 phosphates acetate Chemical class 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 244000052616 bacterial pathogen Species 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- 235000010633 broth Nutrition 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000019262 disodium citrate Nutrition 0.000 description 2
- 239000002526 disodium citrate Substances 0.000 description 2
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000006174 pH buffer Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241001442654 Percnon planissimum Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000018342 monosodium citrate Nutrition 0.000 description 1
- 239000002524 monosodium citrate Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR926515A FR2828M (fr) | 1963-03-01 | 1963-03-01 | Médicament renfermant des colibacilles antibiorésistants. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE644455A true BE644455A (de) | 1964-08-27 |
Family
ID=1345715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE644455A BE644455A (de) | 1963-03-01 | 1964-02-27 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US3369969A (de) |
| BE (1) | BE644455A (de) |
| FR (2) | FR2828M (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3903263A (en) * | 1973-09-18 | 1975-09-02 | Hershey Foods Corp | Composition and method for preventing winter dysentery, diarrhea or ringworm in ruminants |
| US4335107A (en) * | 1978-06-05 | 1982-06-15 | Snoeyenbos Glenn H | Mixture to protect poultry from salmonella |
| CH637297A5 (fr) * | 1978-12-05 | 1983-07-29 | Nestle Sa | Microbille comprenant un microorganisme et son procede de fabrication. |
| US5443826A (en) * | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli |
| DE68928665T2 (de) * | 1988-08-02 | 1998-11-12 | Gastro Services Pty Ltd | Behandlung von gastro-intestinalen krankheiten |
| US5630410A (en) * | 1996-01-04 | 1997-05-20 | Us Navy | Accelerated gas removal from divers' tissues utilizing gas metabolizing bacteria |
| AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| EP3424515A3 (de) | 2010-08-04 | 2019-06-19 | Thomas Julius Borody | Stuhlsammelvorrichtung und deren verwendung |
| US9968638B2 (en) | 2011-03-09 | 2018-05-15 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
| US9719144B2 (en) | 2012-05-25 | 2017-08-01 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
| BR112017024264B1 (pt) | 2015-05-14 | 2022-07-12 | Crestovo Holdings Llc | Composições para transplante de flora fecal e métodos de preparação e utilização das mesmas, e dispositivos para sua administração |
| KR102534545B1 (ko) | 2015-05-22 | 2023-05-18 | 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 | 자폐 스펙트럼 장애 및 관련된 증상을 치료하는 방법 |
| US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| US10849936B2 (en) | 2016-07-01 | 2020-12-01 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
| US20180036352A1 (en) | 2016-08-03 | 2018-02-08 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
| WO2018071537A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| WO2018071536A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating primary sclerosing cholangitis and related disorders |
| US11040073B2 (en) | 2017-04-05 | 2021-06-22 | Finch Therapeutics Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
| EP3606541A1 (de) | 2017-04-05 | 2020-02-12 | Crestovo Holdings LLC | Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit (pd) und verwandten erkrankungen |
| JP2020521760A (ja) | 2017-05-26 | 2020-07-27 | クレストヴォ・ホールディングス・エルエルシー | 糞便微生物ベースの治療剤を含む凍結乾燥組成物ならびにそれを製造および使用する方法 |
| JP2020530494A (ja) | 2017-08-07 | 2020-10-22 | フィンチ セラピューティクス、インコーポレイテッド． | 健康な腸バリアを維持及び回復するための組成物及び方法 |
| US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
| EP3856212A1 (de) | 2018-09-27 | 2021-08-04 | Finch Therapeutics Holdings LLC | Zusammensetzungen und verfahren zur behandlung von epilepsie und damit zusammenhängenden erkrankungen |
| PH12021553137A1 (en) | 2019-07-19 | 2022-07-25 | Finch Therapeutics Holdings Llc | Methods and products for treatment of gastrointestinal disorders |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3072528A (en) * | 1957-07-13 | 1963-01-08 | Med Fabrik Chemisch Pharmazeut | Ingestible dry microorganism preparations |
-
1963
- 1963-03-01 FR FR926515A patent/FR2828M/fr not_active Expired
-
1964
- 1964-02-24 US US347016A patent/US3369969A/en not_active Expired - Lifetime
- 1964-02-27 BE BE644455A patent/BE644455A/fr unknown
-
1968
- 1968-04-16 FR FR148142A patent/FR285F/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR285F (fr) | 1969-12-22 |
| US3369969A (en) | 1968-02-20 |
| FR2828M (fr) | 1964-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BE644455A (de) | ||
| JP5517215B2 (ja) | 発酵及び培養方法、植物発酵エキス、植物発酵エキス末並びに該植物発酵エキス配合物 | |
| JP3810836B2 (ja) | 美容向け化粧料組成物 | |
| CN111278326A (zh) | 改善皮肤、头发和头皮健康的基于酵母的面膜 | |
| JPH03505520A (ja) | 栄養剤組成物及びその製造方法 | |
| KR20060109452A (ko) | 건조 바이오치료 조성물, 용도, 그 투여 장치 및 투여 방법 | |
| US20230381273A1 (en) | Nanoparticle in which antibacterial peptide is encapsulated with chitosan and use thereof | |
| SE9704584L (sv) | Framställning av konjugerad linolsyra | |
| Ferraz et al. | Rothia dentocariosa endocarditis and aortic root abscess | |
| KR100467068B1 (ko) | 락토코쿠스 락티스 씨비티-19, 이를 이용한 항균 배양액분리 농축물의 제조 방법 및 이를 포함하는 화장료 조성물 | |
| JP5502449B2 (ja) | 腸内フローラバランス改善剤及びその製造方法 | |
| EP0850044B1 (de) | Verfahren zur aminosäuregewinnung aus proteinen und verwendung derselben aminosäurehaltigen produkte | |
| WO2020096059A1 (ja) | 育毛用又は脱毛防止用外用剤 | |
| HU186767B (en) | Process for producing compositions for treating dermatologicalanomalys | |
| TWI442928B (zh) | 魚皮發酵產物之製備及用途 | |
| CN101167760B (zh) | 具有抗肿瘤活性的香菇发酵口服液及制备方法 | |
| US9782444B2 (en) | Preparation and use of fish skin fermentation liquid obtained by fermenting fish skin with Aspergillus | |
| JP4360480B2 (ja) | 新規のポリフェノール配糖体並びにこれを含有する化粧料、医薬組成物及び食品 | |
| JP2003113097A (ja) | アウレオバシジウム培養液を含有する外用剤 | |
| CH423096A (fr) | Procédé de préparation d'un médicament bactério-thérapeutique | |
| US12042521B1 (en) | Method for producing a complex composition of turkey tail mushroom extract—chitosan | |
| KR20170114597A (ko) | 세리포리아 락세라타를 함유하는 샴푸 또는 린스 | |
| TWI458438B (zh) | Fermentation and culture methods, plant fermentation extracts, plant fermentation extract powders, and plant fermentation extract complexes | |
| JPH02255620A (ja) | 抗白癬菌剤およびその製造方法、利用方法 | |
| TWI358266B (de) |